Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Trogarzo out in Europe

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Apr 27, 2022 9:50am

71 Views

Post# 34635214

RE:RE:RE:Trogarzo out in Europe

Negotiations in France ( the largest potential market in Europe were "progressing"

I took the retreat in Germany as a negotiation tactic for other countries .....not as the beginning of the end

qwerty22 wrote:

The detail on Germany was a pretty strong signal on the direction things were moving.

palinc2000 wrote: The Feb 24 2022 CC with regards to the status of Trog in Europe did not in my opinion in any way prepare us to declaring defeat 2 months down the road........